Literature DB >> 7835901

Analysis of 133 meioses places the genes for nevoid basal cell carcinoma (Gorlin) syndrome and Fanconi anemia group C in a 2.6-cM interval and contributes to the fine map of 9q22.3.

P A Farndon1, D J Morris, C Hardy, C M McConville, J Weissenbach, M W Kilpatrick, A Reis.   

Abstract

Four disease genes (NBCCS, ESS1, XPAC, FACC) map to 9q22.3-q31. A fine map of this region was produced by linkage and haplotype analysis using 12 DNA markers. The gene for nevoid basal cell carcinoma syndrome (NBCCS, Gorlin) has an important role in congenital malformations and carcinogenesis. Phase-known recombinants in a study of 133 meioses place NBCCS between (D9S12/D9S151) and D9S176. Haplotype analysis in a two-generation family suggests that NBCCS lies in a smaller interval of 2.6 cM centromeric to D9S287. These flanking markers will be useful clinically for gene tracking. Recombinants also map FACC (Fanconi anemia, group C) to the same region, between (D9S196/D9S197) and D9S287. The recombination rate between (D9S12/D9S151) and D9S53 in males is 8.3% and 13.2% in females, giving a sex-specific male:female ratio of 1:1.6 and a sex-averaged map distance of 10.4 cM. No double recombinants were detected, in agreement with the apparently complete level of interference predicted from the male chiasmata map.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7835901     DOI: 10.1006/geno.1994.1528

Source DB:  PubMed          Journal:  Genomics        ISSN: 0888-7543            Impact factor:   5.736


  3 in total

1.  Prevalence, treatment and recurrence of odontogenic keratocyst in central India.

Authors:  Chandrashekhar R Bande; M C Prashant; Bharat Sumbh; P K Pandilwar
Journal:  J Maxillofac Oral Surg       Date:  2010-09-22

2.  Odontogenic Keratocyst: A Case Series of five Patients.

Authors:  K Priya; P Karthikeyan; V Nirmal Coumare
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2012-03-21

3.  Differential allele loss on chromosome 9q22.3 in human non-melanoma skin cancer.

Authors:  E Holmberg; B L Rozell; R Toftgård
Journal:  Br J Cancer       Date:  1996-07       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.